[go: up one dir, main page]

TR200200620T2 - Levosimendan farmasötik solüsyonları - Google Patents

Levosimendan farmasötik solüsyonları

Info

Publication number
TR200200620T2
TR200200620T2 TR2002/00620T TR200200620T TR200200620T2 TR 200200620 T2 TR200200620 T2 TR 200200620T2 TR 2002/00620 T TR2002/00620 T TR 2002/00620T TR 200200620 T TR200200620 T TR 200200620T TR 200200620 T2 TR200200620 T2 TR 200200620T2
Authority
TR
Turkey
Prior art keywords
levosimendan
solutions
pharmaceutical solutions
infusion
levosimendan pharmaceutical
Prior art date
Application number
TR2002/00620T
Other languages
English (en)
Inventor
B�Ckstrom Reijo
Granvik P�ivi
Haikala Ritva
Pelttari Sirpa
Saukko Eva
Yrjol Reija
Original Assignee
Orion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8555263&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200200620(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corporation filed Critical Orion Corporation
Publication of TR200200620T2 publication Critical patent/TR200200620T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Mevcut bulus, farmasötik kullanima ve özellikle de entravenöz uygulamaya yönelik levosimendan solüsyonlari ile ilgilidir. Bulusa ait solüsyonlar yüksek stabiliteye sahip olup, özellikle de enfüzyon veya enjeksiyon solüsyonlari ya da enfüzyon konsantratlari olarak faydalidir. Levosimendan konjestif kalp yetmezligi tedavisinde faydalidir.
TR2002/00620T 1999-09-10 2000-09-08 Levosimendan farmasötik solüsyonları TR200200620T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI991925A FI109659B (fi) 1999-09-10 1999-09-10 Levosimendaanin farmaseuttisia liuoksia

Publications (1)

Publication Number Publication Date
TR200200620T2 true TR200200620T2 (tr) 2002-09-23

Family

ID=8555263

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00620T TR200200620T2 (tr) 1999-09-10 2000-09-08 Levosimendan farmasötik solüsyonları

Country Status (39)

Country Link
US (2) US6730673B1 (tr)
EP (1) EP1210085B1 (tr)
JP (1) JP4708648B2 (tr)
KR (1) KR100869752B1 (tr)
CN (1) CN1203855C (tr)
AR (1) AR025449A1 (tr)
AT (1) ATE315937T1 (tr)
AU (1) AU771027B2 (tr)
BG (1) BG65827B1 (tr)
BR (1) BRPI0013924B8 (tr)
CA (1) CA2382013C (tr)
CO (1) CO5180582A1 (tr)
CZ (1) CZ303095B6 (tr)
DE (1) DE60025627T2 (tr)
DK (1) DK1210085T3 (tr)
EA (1) EA005067B1 (tr)
EE (1) EE05375B1 (tr)
ES (1) ES2256034T3 (tr)
FI (1) FI109659B (tr)
HK (1) HK1049282B (tr)
HR (1) HRP20020298B1 (tr)
HU (1) HU228340B1 (tr)
IL (2) IL148379A0 (tr)
IS (1) IS2244B (tr)
ME (1) ME00523B (tr)
MX (1) MXPA02002423A (tr)
MY (1) MY125984A (tr)
NO (1) NO331989B1 (tr)
NZ (1) NZ517605A (tr)
PL (1) PL202356B1 (tr)
PT (1) PT1210085E (tr)
RS (1) RS50445B (tr)
SI (1) SI1210085T1 (tr)
SK (1) SK287154B6 (tr)
TR (1) TR200200620T2 (tr)
TW (1) TWI242434B (tr)
UA (1) UA73954C2 (tr)
WO (1) WO2001019334A2 (tr)
ZA (1) ZA200201828B (tr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI109659B (fi) * 1999-09-10 2002-09-30 Orion Yhtymae Oyj Levosimendaanin farmaseuttisia liuoksia
FI20010233A0 (fi) * 2001-02-08 2001-02-08 Orion Corp Menetelmä sydämen vajaatoiminnan hoitoon
CN100428937C (zh) * 2003-10-30 2008-10-29 北京海合天科技开发有限公司 左西孟旦冷冻干燥组合物
CN100367964C (zh) * 2004-04-29 2008-02-13 王思清 左西孟旦-β环糊精包含物制剂
CA2596768A1 (en) * 2005-02-18 2006-08-24 Orion Corporation A method for treating heart failure
JP2010514778A (ja) * 2006-12-28 2010-05-06 オリオン コーポレーション 非経口投与のためのレボシメンダン製剤
US10046081B2 (en) 2008-04-11 2018-08-14 The Henry M Jackson Foundation For The Advancement Of Military Medicine, Inc. Electrospun dextran fibers and devices formed therefrom
WO2012093404A2 (en) 2011-01-03 2012-07-12 Gufic Biosciences Limited Parenteral formulations of levosimendan
US20130096479A1 (en) * 2011-10-18 2013-04-18 St. Teresa Medical, Inc. Method of forming hemostatic products
SG10201703789QA (en) * 2012-05-18 2017-06-29 Luoda Pharma Pty Ltd Liquid formulation
CN105106113B (zh) * 2015-09-30 2019-07-26 济南康和医药科技有限公司 一种左西孟旦注射液及其制备方法
HRP20200329T1 (hr) * 2015-11-06 2020-07-24 Carinopharm Gmbh Poboljšane formulacije levosimendana za intravensku primjenu u obliku infuzije ili injekcije i koncentrata infuzije
WO2017083050A1 (en) 2015-11-12 2017-05-18 St. Teresa Medical, Inc. A method of sealing a durotomy
CN108261398A (zh) * 2016-12-30 2018-07-10 齐鲁制药有限公司 一种含有左西孟旦的供注射用药物制剂及其制备方法
WO2019089717A1 (en) 2017-11-02 2019-05-09 St. Teresa Medical, Inc. Fibrin sealant products
CN111474289A (zh) * 2019-10-31 2020-07-31 武汉嘉诺康医药技术有限公司 一种利用反相色谱分离分析左西孟旦中右西孟旦的方法
AU2020408323A1 (en) 2019-12-16 2022-08-11 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HF-pEF)
CN111514147B (zh) * 2020-05-12 2021-09-17 成都欣捷高新技术开发股份有限公司 用于急性失代偿心力衰竭症状的左西孟旦钠药用组合物及制备方法
US11760730B2 (en) * 2021-01-11 2023-09-19 Navinta, Llc Process for the preparation of high purity Levosimendan
WO2023027670A2 (en) * 2021-08-23 2023-03-02 Tum Ekip Ilac Anonim Sirketi Lyophilized levosimendan compositions
CN115518037A (zh) * 2022-10-14 2022-12-27 上药东英（江苏）药业有限公司 一种安全质量稳定的左西孟旦注射剂组合物及其制备方法
CN116473930B (zh) * 2023-05-17 2023-12-15 山东泰合医药科技有限公司 一种注射用左西孟旦及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2251615B (en) 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
GB2266841A (en) 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
GB9606474D0 (en) 1996-03-27 1996-06-05 Orion Yhytmo Oy Method for obtaining pure enantiomers of a pyridazinone derivative
GB9614098D0 (en) * 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
FI980902A7 (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaanin stabiileja koostumuksia
FI109659B (fi) * 1999-09-10 2002-09-30 Orion Yhtymae Oyj Levosimendaanin farmaseuttisia liuoksia

Also Published As

Publication number Publication date
EA200200348A1 (ru) 2002-08-29
YU16902A (sh) 2004-09-03
AU771027B2 (en) 2004-03-11
KR20020048400A (ko) 2002-06-22
NO331989B1 (no) 2012-05-21
JP2003509351A (ja) 2003-03-11
FI109659B (fi) 2002-09-30
PL354028A1 (pl) 2003-12-15
HUP0202749A2 (hu) 2003-02-28
CN1203855C (zh) 2005-06-01
HUP0202749A3 (en) 2003-03-28
HK1049282A1 (en) 2003-05-09
ZA200201828B (en) 2003-08-27
EA005067B1 (ru) 2004-10-28
EP1210085A2 (en) 2002-06-05
IS2244B (is) 2007-05-15
CZ303095B6 (cs) 2012-03-28
HRP20020298A2 (en) 2003-06-30
MY125984A (en) 2006-09-29
CA2382013C (en) 2009-08-11
FI19991925L (fi) 2001-03-10
KR100869752B1 (ko) 2008-11-21
BR0013924B1 (pt) 2013-09-24
HK1049282B (zh) 2005-12-30
IS6296A (is) 2002-03-06
NO20021090D0 (no) 2002-03-05
TWI242434B (en) 2005-11-01
CN1373665A (zh) 2002-10-09
EE05375B1 (et) 2011-02-15
UA73954C2 (uk) 2005-10-17
WO2001019334A3 (en) 2001-11-15
SK3272002A3 (en) 2002-12-03
IL148379A (en) 2006-12-10
RS50445B (sr) 2010-03-02
BR0013924A (pt) 2002-05-21
WO2001019334A2 (en) 2001-03-22
NO20021090L (no) 2002-03-05
CO5180582A1 (es) 2002-07-30
DK1210085T3 (da) 2006-05-08
BG65827B1 (bg) 2010-02-26
ES2256034T3 (es) 2006-07-16
IL148379A0 (en) 2002-09-12
ME00523B (me) 2011-10-10
DE60025627T2 (de) 2006-11-16
ATE315937T1 (de) 2006-02-15
NZ517605A (en) 2003-08-29
AR025449A1 (es) 2002-11-27
EP1210085B1 (en) 2006-01-18
US20040106617A1 (en) 2004-06-03
SK287154B6 (sk) 2010-01-07
AU7004400A (en) 2001-04-17
PT1210085E (pt) 2006-05-31
US6943164B2 (en) 2005-09-13
CZ2002788A3 (cs) 2002-11-13
BRPI0013924B8 (pt) 2021-05-25
BG106589A (bg) 2002-11-29
MXPA02002423A (es) 2002-08-12
US6730673B1 (en) 2004-05-04
CA2382013A1 (en) 2001-03-22
SI1210085T1 (sl) 2006-04-30
DE60025627D1 (de) 2006-04-06
PL202356B1 (pl) 2009-06-30
JP4708648B2 (ja) 2011-06-22
HRP20020298B1 (hr) 2007-02-28
EE200200129A (et) 2003-04-15
HU228340B1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
TR200200620T2 (tr) Levosimendan farmasötik solüsyonları
NO20015584D0 (no) Lantidsvarende insulintrofiske peptider
TR200102805T2 (tr) Glikokinaz aktivatörleri
CA2400318A1 (en) Botulinum toxin pharmaceutical compositions
MX9603925A (es) Combinaciones de anticoagulantes y proteinas activas tromboliticamente, y usos de las mismas.
MXPA02002895A (es) Tratamiento topico de infecciones por estreptococcus.
BR0113643A (pt) Compostos de guanidinobenzamidas como agonistas de mc4-r e seus usos
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
YU48099A (sh) Kompozicija koja obuhvata hranljivi materijal i biljku i njena upotreba
TR200003635T2 (tr) Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması.
BG106171A (en) Compositions and uses of et743 for treating cancer
AU1795101A (en) Safety mechanism to prevent accidental patient injection and methods of same
WO1999056723A3 (en) Hemoglobine-haptoglobin complexes for targeted drug delivery
DE60018569D1 (de) Neue verwendung von hypoosmotischen salinelösungen und darauf basierendem medikament
SE9900043D0 (sv) New use
DE69821498D1 (de) Verwendung von amifostin
DE60222383D1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
WO1999061014A3 (en) Compositions and methods employing r(-) fluoxetine and other active ingredients
DE50113974D1 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
NZ514911A (en) Use of N-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients
GB0018322D0 (en) Pharmaceutical compositions
BR0112035A (pt) peptìdeos antimicrobianos de novispirin
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
PT1150981E (pt) Composto nucleosidico terapeutico
EA200300368A1 (ru) Применение аргинина при получении лекарственного средства для профилактики и лечения побочных эффектов, связанных с внутривенным введением фармацевтических препаратов